cyclosporin-g and Lupus-Erythematosus--Systemic

cyclosporin-g has been researched along with Lupus-Erythematosus--Systemic* in 3 studies

Other Studies

3 other study(ies) available for cyclosporin-g and Lupus-Erythematosus--Systemic

ArticleYear
Cyclosporine A and cyclosporine G enhance IgG rheumatoid factor production in MRL/lpr mice.
    Transplantation proceedings, 1988, Volume: 20, Issue:3 Suppl 4

    Topics: Animals; Antibodies, Antinuclear; Cyclosporine; Cyclosporins; Immunoglobulin G; Leukocyte Count; Lupus Erythematosus, Systemic; Lymphoid Tissue; Lymphoproliferative Disorders; Mice; Mice, Inbred Strains; Mice, Mutant Strains; Organ Size; Rheumatoid Factor; Stimulation, Chemical

1988
Ciclosporin treatment in experimental autoimmune myasthenia gravis.
    Monographs in allergy, 1988, Volume: 25

    Topics: Animals; Autoantibodies; Cyclosporine; Cyclosporins; Diabetes Mellitus, Type 1; Disease Models, Animal; Female; Lupus Erythematosus, Systemic; Mice; Mice, Inbred NZB; Myasthenia Gravis; Rats; Rats, Inbred BB; Rats, Inbred Lew

1988
Successful treatment of autoimmunity in (NZB X NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: I. Reduction of autoantibodies.
    Clinical and experimental immunology, 1986, Volume: 64, Issue:2

    Autoimmune (NZB X NZW)F1 mice were treated with the immunosuppressive agent, cyclosporin, and its new derivative (Nva2)-cyclosporin. Both compounds prevented the development of autoantibodies in young mice, and also reduced the levels of the autoantibodies in old mice. These findings established that autoantibodies, at least in the (NZB X NZW)F1 mice, can be controlled pharmacologically. This study supports the possibility that treatment with cyclosporin and (Nva2)-cyclosporin might be effective in the treatment of certain autoimmune diseases in man.

    Topics: Age Factors; Animals; Antibodies, Antinuclear; Autoantibodies; Autoimmune Diseases; Cyclosporine; Cyclosporins; DNA; Erythrocytes; Lupus Erythematosus, Systemic; Mice; Mice, Inbred NZB

1986